Medivir AB (publ) is a Sweden‐based biotechnology company focused on the discovery, development and commercialization of innovative therapies for oncology and viral diseases. Founded in 1988 and headquartered in Huddinge, Stockholm County, Medivir has evolved from its original emphasis on antiviral research into a specialized oncology player with a robust small-molecule pipeline. The company’s early success in hepatitis C treatment led to a strategic out-licensing agreement for the antiviral simeprevir (Olysio®) with Janssen, laying the groundwork for ongoing reinvestment in cancer drug development.
Today, Medivir’s core business revolves around a portfolio of discovery and development programs targeting both hematological malignancies and solid tumors. Its preclinical and clinical-stage assets include small-molecule kinase inhibitors, tumor-activated prodrugs and novel mechanism compounds designed to address areas of high unmet need. Among the most advanced initiatives is a first-in-human study of a proprietary liver-cancer candidate, as well as explorations into tumor microenvironment modulation and immune system engagement, reflecting the company’s commitment to diversified oncology strategies.
Medivir maintains collaborative partnerships with academic institutions and contract research organizations across Europe and North America. These alliances support biomarker discovery, translational research and clinical trial execution in key markets. Although based in Sweden, the company’s research and development efforts extend to global sites, leveraging international expertise in medicinal chemistry, pharmacology and oncology clinical practice to accelerate program timelines and enhance development outcomes.
Leadership at Medivir comprises a seasoned management team and board of directors with deep roots in pharmaceutical and biotechnology industries. Drawing on decades of experience in drug discovery, regulatory affairs and commercial strategy, the company’s executives steer a lean organization structured to advance high-value assets from laboratory to clinic. With a clear strategic focus and a track record of successful collaborations, Medivir continues to pursue its mission of delivering novel cancer therapies that improve patient outcomes worldwide.
AI Generated. May Contain Errors.
